



Amendments to the Claims. (**material to be inserted is in bold and underline, material to be deleted is in [brackets and strikeout]**).


1. (Amended) The use of a compound represented with the following general formula (I) for RANTES induction:



[wherein


R<sup>1</sup> represents a hydrogen atom or a group of the following formula (II) or (III):





{wherein[5] the groups of formula (II) and formula (III) may also be their pharmaceutically acceptable salts};

R<sup>2</sup> represents COOH or a group of the following formula (IV):



or their pharmaceutically acceptable salts;

X represents C=O or CH; and,

dotted lines suitably represent a double bond].

2. (Amended) The use according to claim 1, wherein the pharmaceutically acceptable salts in the above formulas (II), (III) and (IV) are sodium salts, potassium salts, ammonium salts or combinations thereof.

3. (Amended) The use of a compound according to claim 1, wherein[5] a compound of the above general formula (I) is one of either:

sodium olean-3 $\beta$ -hydroxy-11-oxo-12-ene-30-ate;  
disodium olean-9(11),12-diene-3 $\beta$ ,30-diol-3 $\beta$ ,30-O-dihemipthalate;  
disodium olean-11,13(18)-diene-3 $\beta$ ,30-diol-3 $\beta$ ,30-O-dihemipthalate;  
disodium olean-3 $\beta$ -hydroxy-11,13(18)-diene-30-ate-3 $\beta$ -O-hemipthalate;  
disodium olean-3 $\beta$ -hydroxy-11-oxo-12-ene-30-ate-3 $\beta$ -O-hemipthalate; or  
monoammonium 20 $\beta$ -carboxy-11-oxo-30-norolean-12-en-3 $\beta$ -yl-2-O- $\beta$ -D-glucopyranuronosyl- $\beta$ -D-glucopyranosidouronate.

4. (Amended) The use of a compound according to any one of claims 1 to 3 in the production of a RANTES inducer.

5. (Amended) A RANTES induction method comprising: administration of a compound according to any one of claims 1 to 3 in an amount effective for RANTES induction.

6. (Original) A pharmaceutical composition comprising: containing a


compound according to claim 1 with an arbitrary pharmaceutically acceptable carrier in an amount effective for treating or preventing decreases in infection resistance to opportunistic infections occurring in burn patients, AIDS patients, cancer patients, encephalitis patients, individuals having suffered serious injuries or undergone major surgery, or individuals subject to stress.

**"Express Mail" Mailing Label No. EV316281655US**  
**Date of Deposit – October 27, 2003**

I hereby certify that the attached correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Alexandria, Virginia 22313.

  
George Painter

Respectfully submitted,  
KOLISCH HARTWELL, P.C.

  
Anton E. Skaugset  
Customer No. 23581  
Registration No. 38,617  
of Attorneys for Applicants  
520 S.W. Yamhill Street, Suite 200  
Portland, Oregon 97204  
Telephone: (503) 224-6655  
Facsimile: (503) 295-6679